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Abstract
Aim This study examined modifications in secondary pre-
ventive medication between the time of hospital discharge
(HD) and during a 6-month follow-up treatment of outpatients
with acute coronary syndromes (ACS) and stroke.
Subjects and methods During a 6-month period, a health
diary was completed on a weekly basis by 98 patients who
were initially hospitalised with ACS and 29 patients with
strokes in the Cologne area (Germany). Changes in
medication between the time of HD and follow-up
treatment (weeks 2, 12, and 24) were recorded.
Results On average, patients with ACS took six medica-
tions, whereas patients with stroke took five medications
per day. ACS patients received beta-blockers (96%), lipid-
lowering agents (80%), and angiotensin-converting enzyme
(ACE) inhibitors (64%) at HD, and no changes in
medication were made during follow-up treatment. How-
ever, there was a significant decrease in prescriptions of
clopidogrel among ACS patients within 6 months, and
about 13% of ACS patients did not receive an antiplatelet
agent at any time. Stroke patients received beta-blockers
(50%), lipid-lowering agents (67%), and antiplatelet agents,
such as acetylsalicylic acid (57%) or clopidogrel (27%), at
the time of HD, and no significant changes in medication
were instituted during follow-up treatment.
Conclusion Treatment of ACS patients with the combina-
tion of acetylsalicylic acid and clopidogrel was insufficient,
although it has been shown that this combination is highly
effective in secondary prevention of ACS. Besides medical
reasons, the cost-containment restrictions (“medication
budget”) for German physicians might explain the observed
failure of guideline-oriented medication. Furthermore, no
changes in medications occurred regarding blood-pressure-
and lipid-lowering agents.
Keywords Acute coronary syndrome . Stroke .
Secondary prevention . Primary care
Abbreviations
ACE angiotensin converting enzyme
ACS acute coronary syndromes
ATC Anatomical Therapeutic Chemical
(classification system)
HD hospital discharge
OTC over the counter (drugs)
Introduction
Changes in medications between ambulatory and stationary
treatment have been examined in several publications with
regard to interface problems. As a result, modifications in
pharmaceutical treatment were found to various degrees
and at different stages in the course of continued medical
care (Hach et al. 2005; Himmel et al. 2004; Taxis and
Schneeweiss 2003). Inconsistency in prescription behaviour
is especially problematic when dealing with medications
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with a proven benefit for preventing serious adverse health
conditions. For example, the need for pharmaceutical
approaches to secondary prevention of acute coronary
syndromes (ACS) and stroke have increasingly gained
recognition and acceptance during the last 2 decades
(Jamieson 2007; Phillips 1999). In this regard, national
and international therapeutic guidelines for the prevention
of secondary stroke and coronary events have been
developed (e.g., Bundesärztekammer et al. 2006; Bertrand
et al. 2002; Braunwald et al. 2002; Joint Guidelines issued
by the German Neurological Society and the German
Stroke Society 2005). As outlined in these therapeutic
guidelines, antiplatelet, antihypertensive, and lipid-lowering
therapies are known to significantly reduce the risk of
recurrence of macrovascular diseases, such as coronary and
cerebrovascular diseases. Contrary to this, national and
international studies have shown that these guidelines are
not yet fully implemented in primary and secondary
prevention with respect to platelet aggregation inhibitors,
angiotensin-converting enzyme (ACE) inhibitors, beta-
blockers, and statins (EUROASPIRE I and II Group
2001; Krumholz et al. 1998; Welterman et al. 1997) in the
prevention of ACS. However, long-term secondary stroke
prevention in Germany has revealed better findings,
especially with regard to antithrombotic medications
(Hamann et al. 2003). Even though therapeutic guideline
implementation has improved over the past years
(Mandelzweig et al. 2006; Wienbergen et al. 2001), only
few studies in Germany have examined whether treatment
recommendations after hospital discharge were according to
current guidelines and to what extent these recommenda-
tions were realised in subsequent primary care (Zeymer et
al. 2007). The goal of this study was to compare treatment
recommendations for secondary pharmacological preven-
tion of ACS and stroke after hospital discharge with current
guidelines and to examine changes in medication between
initial hospitalisation and continued medical care.
Methods
Patients with ACS or stroke, who were treated in five
hospitals in the Cologne area (Germany) between April
2005 and November 2005, were observed for 6 months after
hospital discharge in a prospective study. Inclusion criteria for
the study were as follows: admission diagnosis of ACS, as
coded for by the hospital’s administrative database (ICD-10
codes I20.0, I20.8, and I21); admission diagnosis of cerebral
infarction or stroke (ICD-10 codes I63 and I64); and age
>18 years with the cognitive and intellectual capability to
participate in the study. Of the initially 970 hospitalised
patients, 408 were excluded due to meeting the exclusion
criteria: (1) very poor general health condition (35%), (2) low
cognitive capability (14%), (3) lack of substantial knowledge
of the German language (15%), (4) participation in other
clinical studies (3%), and (5) other reasons (7%), or (6) due to
early hospital discharge (26%). Of the remaining 562
potentially qualified patients, 216 (38%) gave their consent
to participate in the study. The dropout rate of the included
216 patients totalled 41%. Patients` reasons for drop out were:
(1) “no longer interested” (69%), (2) “poor general health
condition” (18%), (3) “too time-consuming” (8%), and (4)
“too difficult” (6%). Thus, the remaining study population
consisted of 127 patients (98 patients with ACS and 29
patients with stroke).
Data acquisition was pursued in three steps. During the
initial hospitalisation or shortly after, patients completed a
standardised questionnaire (step 1). The questionnaire
captures socio-demographic data and information regarding
the patient’s general health. At the time of hospital
discharge, each patient was given a questionnaire with a
weekly health diary (step 2). The appropriate questionnaire
was filled in by the patients on a weekly basis for 6 months
following HD. The questionnaire covered aspects of
general health, medications (brand name), dosing, change
in medications, and the underlying reasons for medication
changes. The third step of data acquisition was conducted
by a study nurse for case documentation. Following a
standardised procedure, information regarding admission
and HD diagnosis (ICD-10), medications, stationary diag-
nosis and therapy, and follow-up treatments were obtained
from the patient’s medical records and HD summary.
The medication was classified according to the WHO’s
Anatomical Therapeutic Chemical (ATC) classification sys-
tem (Dimdi 2005). Over-the-counter (OTC) drugs, topical
medications, acute medications (e.g., antibiotics, immunmo-
dulatories, and antineoplastics), homoeopathic medications,
herbal agents, and enzymes were not included in the study.
Statistical analyses were performed using SPSS 12.0 and
15.0 (Statistical Package for the Social Sciences). Patient
characteristics and medication data are presented in absolute
and relative frequencies. In addition, for each medication a
Cochran’s Q test was performed to test for differences
between the frequencies of prescription over time. An α-
adjustment (0.05) for multiple testing was performed by
means of the Bonferroni procedure (Table 2). Due to the
small sample size of this study, all available complete data
sets were used for statistical analysis. Therefore, there were
104 ACS patients enclosed at hospital discharge and week 2
and 30 stroke patients from HD until week 12.
Results
The demographic characteristics of the patient groups are
presented in Table 1. Patients with ACS took an average six
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medications per day within the observation period (minimum
at week 24=0 and maximum at week 24=14), whereas
patients with a stroke took five different medications per day
(minimum at week 24=1 and maximum at week 24=10).
Of all patients with ACS, 100 (96%) received a beta-
blocker, 16 (15%) used a vasodilator used for cardiac
disease (organic nitrates and other vasodilators, e.g.,
molsidomine and trapidil), 83 (80%) used a lipid-lowering
agent, and 67 (64%) used an ACE inhibitor at the time of
HD. Eighty-nine (86%) of all study patients with ACS used
acetylsalicylic acid and 58 (56%) clopidogrel as antiplatelet
agents at the time of HD (Table 2). No change in
medications was observed 2 weeks following HD. In week
24, a minor increase in the use of vasodilators 18% (p=
0.188) and a slight, however, due to the adjusted α-level
(α*=0.003) not statistically significant decline in prescrip-
tions of beta-blockers 93% (p=0.010) was observed.
Furthermore, a significant decrease (p=0.002) of clopidog-
rel prescriptions [42 patients (43%)] and a non-significant
decline (p=0.012) in the use of acetylsalicylic acid [76
Table 2 Prescriptions of medications with therapeutic guideline recommendations































Vasodilators 15.4 21.2 19.4 18.3 0.188 0 0 0 0 –
Beta-blockers 96.2 91.3 90.8 92.9 0.010 50.0 46.7 50.0 48.3 0.875
Calcium channel
blockers
9.6 8.7 11.2 11.2 0.629 10.0 6.7 13.3 13.8 0.194
ACE inhibitorsb 64.4 65.4 60.2 60.2 0.380 43.3 40.0 43.3 44.8 0.572
Angiotensin II
antagonists
16.3 15.4 19.4 18.4 0.172 13.3 13.3 13.3 13.3 1.000
Lipid-lowering agents 79.8 83.7 82.6 83.7 0.442 66.7 60.0 66.7 65.5 0.682
Clopidogrel 55.8 54.8 52.0 42.9 0.002 26.7 23.3 16.7 20.7 0.479
Ticlopidine 0 1,0 1,0 1,0 0.392 0 0 0 0
Acetylsalicylic acid 85.6 85.6 78.6 77.6 0.012 56.7 50.0 60.0 65.5 0.525
Adjusted α-level: α*=0.05/16=0.003
a Cochran’s Q test; b (ACE) angiotensin-converting enzyme inhibitors
Table 1 Patient characteristics at hospital discharge
Acute coronary syndromes Stroke
Gender Male 73.1% (76) 60.0% (18)
Female 26.9% (28) 40.0% (12)
Admission diagnosis Acute myocardial infarction (I21) 34.6% (36)
Unstable angina (I20) 65.4% (68)
Cerebral infarction (I63) 80.0% (24)
Stroke, not specified (I64) 20.0% (6)
Hospital Tertiary care 85.6% (89) 30.0% (9)
Primary care 10.6% (11) 63.3% (19)
Comprehensive care 3.8% (4) 6.7% (2)
Native language German 92.3% (96) 100.0% (30)
Other 7.7% (8) 0%
Age <=40 years 3.8% (4) 0%
41–50 years 13.5% (14) 10.0% (3)
51–60 years 23.1% (24) 16.7% (5)
61–70 years 39.4% (41) 46.7% (14)
71–80 years 17.3% (18) 23.3% (7)
>=81 years 2.9% (3) 3.3% (1)
Length of hospitalisation Median (days) 4 9
Minimum (days) 1 3
Maximum (days) 30 34
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patients (78%)] occurred in week 24. Of all ACS patients,
11% did not receive any antiplatelet agent at hospital
discharge as well as 12% at week 2 and week 12 and 16%
at week 24. However, 52% of the patients at HD and 2
weeks later were treated with acetylsalicylic acid and
clopidogrel in combination. Furthermore, a decrease in the
use of the combination therapy was observed in week 12
(43%) and week 24 (37%), respectively.
Of all patients with stroke, 15 (50%) received a beta-
blocker, 13 (43%) used an ACE inhibitor, 3 (10%) used a
calcium channel blocker, 20 (67%) used a lipid-lowering
agent, 17 (5%) used acetylsalicyclic acid, and 8 (27%) used
clopidogrel at the time of hospital discharge (Table 2). No
significant changes in medication were observed within
24 weeks. With regard to antiplatelet agent therapy, about 6
out of 30 patients did not receive any treatment throughout
the observation time.
Data quality was assessed by comparing the prescribed
medication as indicated on the physician questionnaires
(n=28) with the medication documented in the health diaries
(weeks 1–21). The data showed an agreement of 90.5%
between the reports submitted by the patients and the
physicians.
Discussion
The present study revealed a remarkably high number of
ACS patients receiving antiplatelet medication (89%), beta-
blockers (96%), lipid-lowering agents (80%), and ACE
inhibitors (64%) when compared with earlier publications.
Only the results from the Acute Myocardial Infarction
(MITRA 1 + 2) and Myocardial Infarction (MIR) Registries
showed a higher treatment rate of patients with ACE
inhibitors (76%) at the time of HD (Gottwik et al. 2001). In
contrast, EUROASPIRE-II reported that 84% of ACS
patients received antiplatelet medication, 66% received
beta-blockers, 63% received lipid-lowering agents, and
43% received ACE inhibitors (EUROASPIRE I and II
Group 2001). Less positive, however, are the results of the
DETECT-Study, reflecting the medication of patients with
coronary artery disease in a German outpatient setting
(Bischoff et al. 2006). Observed prescription rates for
antiplatelet medication were 53%, for beta blockers 57%,
for statins 43%, and for ACE inhibitors 50%. Furthermore,
on closer examination, the apparently positive results of the
present study concerning the antiplatelet medication of
ACS patients are also less satisfactory. Only 52% of all
ACS patients were treated with acetylsalicylic acid and
clopidogrel in combination. These are insufficient results,
since the combination of both antiplatelet agents was shown
to be highly effective in secondary prevention of vascular
events and in preventing coronary stent thrombosis.
Compared to acetylsalicylic acid alone, a combination of
clopidogrel and acetylsalicylic acid decreases the number of
cardiovascular events in patients with ACS by 20% (CURE
Study Investigators 2001). In addition, a decline of the
combination therapy was observed in week 12 (43%) and
week 24 (37%), respectively. Therefore, for at least 9 months
the guideline-recommended secondary medical prevention
of ACS with the combination of acetylsalicylic acid and
clopidogrel was not yet consistently implemented (Hamm et
al 2004a, 2004b; Silber et al. 2005). Aside from some
medical reasons (e.g., side effects), the cost-containment
restrictions (“medication budget”) for German physicians
might explain the observed failure of guideline-oriented
medication. Hypertensive, antiplatelet, and lipid-lowering
therapies are also known to reduce the risk of recurrence of
cerebrovascular disease (Jamieson 2007). Based on these
findings, the medications prescribed to patients with stroke
seemed to be in concordance with current guideline
recommendations. Specifically, >50% of patients received
an antihypertensive medication, >80% of patients received
an antithrombotic medication, and about 70% of patients
were given a lipid-lowering agent. Several study patients
had suffered a cerebral event coded as “unspecified stroke”
(ICD-10: I64), which might have included cases of
hemorrhagic stroke. This could be an explanation for why
six patients (20%) did not receive any antithrombotic
medication after HD. Except for antiplatelet medication,
no changes in prescriptions were observed during the
observation period for ACS patients. However, vasodilators
used in cardiac diseases were prescribed more often (an
increase of 3%), while beta-blockers had a lower prescrip-
tion rate after 24 weeks (a decrease of 3%). This may
indicate that some of the attending physicians focused on
symptomatic treatment of the medical condition. Patients
with ACS took an average of six medications and patients
with stroke took an average of five medications, which is in
the upper range reported in the literature (Hach et al. 2005;
Harder et al. 2005). It was also found that polypharmacy
can be caused by treatment according to evidence-based
therapeutic guidelines, which is particularly problematic for
elderly and multi-morbid patients (Meinertz and Kähler
2005). However, the administration of various drugs at
various times of the day with different instructions can be
very demanding and may result in low compliance,
especially for geriatric patients (Kidd and Altmann 2000).
The employed method involving a health diary yielded
sufficiently high data quality, as supported by the overall
high agreement with regard to medication documentation
by patients and physicians (>90%). However, it was
difficult to motivate the physicians conducting further
treatment to participate in this study (physician question-
naire: first contact after HD, n=28), and those who
participated did not fully document medication-related infor-
6 J Public Health (2009) 17:3–7
mation, e.g., reasons for a change in medications. The
findings of this study are therefore limited to a small sample
size. This must especially be kept in mind when interpreting
the results of the patients with stroke (n=30). These data were
obtained at five hospitals within the Cologne area and
approximately 86% of the patients were hospitalised in a
tertiary care hospital. Therefore, it is not known with certainty
to what degree these results can be generalised. In conclusion,
the results of our study as well as the results of the DETECT-
study (Bischoff et al. 2006) indicate an undersupply of ACS
patient with antiplatelet agents, especially in outpatient care.
In particular, the combination therapy with acetylsalicylic acid
and clopidogrel seemed to not be sufficient in all cases. Future
studies, particularly in German outpatient settings, with
longitudinal design and representative samples should focus
on this problem.
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